# Efficacy, Safety, and Tolerability of Ambien (Zolpidem) in the Treatment of Children Ages 6 to 17 With Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia

> **NCT00318448** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 201 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** Zolpidem (SL800750)

## Key facts

- **NCT ID:** NCT00318448
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2006-08
- **Final completion:** 2006-08
- **Target enrollment:** 201 (ACTUAL)
- **Last updated:** 2009-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00318448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00318448, "Efficacy, Safety, and Tolerability of Ambien (Zolpidem) in the Treatment of Children Ages 6 to 17 With Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00318448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*